Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025
Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, March 27, 2025 after market close.
The company will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Investors can access the live call by dialing 888-506-0062 (domestic) or 973-528-0011 (international) with conference code 733956. The webcast will be available on Clearside's website under the Investors section: Events and Presentations.
Clearside Biomedical (Nasdaq: CLSD), un'azienda biofarmaceutica focalizzata sulla fornitura di terapie per la parte posteriore dell'occhio attraverso lo spazio suprachoroidale (SCS®), ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per giovedì 27 marzo 2025 dopo la chiusura del mercato.
L'azienda ospiterà un webcast e una conferenza telefonica alle 16:30 ora orientale per discutere i risultati e fornire un aggiornamento aziendale. Gli investitori possono accedere alla chiamata dal vivo componendo il numero 888-506-0062 (nazionale) o 973-528-0011 (internazionale) con il codice conferenza 733956. Il webcast sarà disponibile sul sito web di Clearside nella sezione Investitori: Eventi e Presentazioni.
Clearside Biomedical (Nasdaq: CLSD), una empresa biofarmacéutica centrada en ofrecer terapias para la parte posterior del ojo a través del espacio suprachoroidal (SCS®), ha programado el anuncio de los resultados financieros del cuarto trimestre y del año completo 2024 para jueves 27 de marzo de 2025 después del cierre del mercado.
La empresa llevará a cabo un webcast y una llamada de conferencia a las 4:30 p.m. hora del Este para discutir los resultados y proporcionar una actualización corporativa. Los inversores pueden acceder a la llamada en vivo marcando el 888-506-0062 (nacional) o 973-528-0011 (internacional) con el código de conferencia 733956. El webcast estará disponible en el sitio web de Clearside en la sección de Inversores: Eventos y Presentaciones.
Clearside Biomedical (Nasdaq: CLSD), 안구 후부에 치료제를 전달하는 데 중점을 둔 생명공학 회사로, 초코로이드 공간(SCS®)을 통해 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 27일 목요일 시장 마감 후로 예정하였습니다.
회사는 동부 표준시 오후 4시 30분에 결과를 논의하고 기업 업데이트를 제공하기 위해 웹캐스트 및 컨퍼런스 콜을 개최할 것입니다. 투자자들은 888-506-0062(국내) 또는 973-528-0011(국제)로 전화하여 회의 코드 733956로 생방송에 참여할 수 있습니다. 웹캐스트는 Clearside의 웹사이트 투자자 섹션: 이벤트 및 발표에서 확인할 수 있습니다.
Clearside Biomedical (Nasdaq: CLSD), une entreprise biopharmaceutique axée sur la fourniture de thérapies pour l'arrière de l'œil à travers l'espace suprachoroïdal (SCS®), a prévu l'annonce de ses résultats financiers du quatrième trimestre et de l'année entière 2024 pour jeudi 27 mars 2025 après la fermeture du marché.
L'entreprise organisera un webcast et une conférence téléphonique à 16h30 heure de l'Est pour discuter des résultats et fournir une mise à jour sur l'entreprise. Les investisseurs peuvent accéder à l'appel en direct en composant le 888-506-0062 (national) ou le 973-528-0011 (international) avec le code de conférence 733956. Le webcast sera disponible sur le site Web de Clearside dans la section Investisseurs : Événements et Présentations.
Clearside Biomedical (Nasdaq: CLSD), ein biopharmazeutisches Unternehmen, das sich darauf konzentriert, Therapien für den hinteren Teil des Auges über den suprachoroidalen Raum (SCS®) bereitzustellen, hat die Bekanntgabe seiner finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 auf Donnerstag, den 27. März 2025, nach Börsenschluss angesetzt.
Das Unternehmen wird um 16:30 Uhr Eastern Time ein Webcast und eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Investoren können an dem Live-Call teilnehmen, indem sie 888-506-0062 (national) oder 973-528-0011 (international) mit dem Konferenzcode 733956 wählen. Der Webcast wird auf der Website von Clearside im Bereich Investoren: Veranstaltungen und Präsentationen verfügbar sein.
- None.
- None.
ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2024 financial results will be reported on Thursday, March 27, 2025 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-506-0062 (domestic) or 973-528-0011 (international) and entering conference code: 733956. The Company suggests participants join 15 minutes in advance of the event.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), is in development for the treatment of neovascular age-related macular degeneration (wet AMD). Planning for a Phase 3 program is underway. In addition, Clearside is evaluating various small molecules for the potential long-acting treatment of geographic atrophy (GA). Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X.
Source: Clearside Biomedical, Inc.
Investor and Media Contacts: Jenny Kobin Remy Bernarda ir@clearsidebio.com
FAQ
When will Clearside Biomedical (CLSD) release its Q4 and full year 2024 earnings?
How can investors join Clearside Biomedical's Q4 2024 earnings call?
What time is Clearside Biomedical's (CLSD) Q4 2024 earnings call?
Where can I find the webcast for CLSD's Q4 2024 earnings call?
